PRODUCT INFORMATION SHEET

Monoclonal antibodies detecting human antigens

CD103 FITC **CD22** R-PE IVD REF IQP-227FR 50 tests

IVD CE ***In Vitro Diagnostic medical device***

Description

CD103 *Clone* **B-ly7** *Isotype* **murine IgG1**

For detailed description of this particular single reagent, please refer to IQP-111, CD103 (B-ly7)

CD22 *Clone* **B-ly8** *Isotype* **murine IgG1**

For detailed description of this particular single reagent, please refer to IQP-110, CD22 (B-ly8)

Intended use

CD103/CD22 dual combination, IQP-227FR, is a direct immunofluorescence reagent used for detection and follow-up of B cell malignancies. The specificity of B-ly7 for diagnosis of HCL can be enhanced using double staining protocols with B cell markers such as CD22. CD22 antibodies are used in flow cytometry and immunohistochemistry as a pan B cell reagent, for the immunophenotyping of B cell lymphomas and HCL. It is more strongly expressed on prolymphocytic leukemia and HCL than in chronic lymphocytic leukemia. B cell lineage ALL, express membrane and cytoplasmic CD22.

Summary

HCL is a rare disorder and HCL cells may be present as bone marrow infiltrates or as circulating leukemic cells in the blood. The aE integrin appears to be expressed especially on activated T and B cells, and activated monocytes, which normally comprise a small percentage of blood leukocytes.
B-ly7 is a routinely applied marker for detection and follow-up of B cell malignancies. The specificity of B-ly7 for diagnosis of HCL can be enhanced using double staining protocols with B cell markers such as CD19 or CD22.

Applications

B-ly7 recognizes an integrin containing the aE subunit which dimerizes with the b7 chain, present on hairy leukemia cells, to form the HML-1 (human mucosal lymphocyte) antigen. Monoclonal antibody B-ly7 (CD103) is strongly reactive with hairy cell leukemia (HCL), a subtype of B cell chronic lymphocytic leukemia, but not with other B cell leukemias or lymphomas. B-ly7 is frequently used for the diagnosis of HCL together with CD19. CD103 is expressed primarily on intra-epithelial lymphocytes and on 1-2% of peripheral blood lymphocytes. Its expression can be upregulated by lymphocyte mitogens, such as phorbol ester. The function of this integrin is related to T cell interaction with epithelium and to T cell adhesion.

CD22 is detected in the cytoplasm early in B cell development (late pro-B cell stage), appears on the cell surface simultaneously with surface IgD, and is found on most mature B cells. Expression is lost with terminal differentiation of B cells and is absent on plasma cells. Activation of B cells via surface Ig increases CD22 expression. CD22 reacts with most B cell leukemias including Hairy Cell Leukemia (HCL) and B cell lymphomas.

Note: Not all the applications mentioned are performed using IQ Products reagents.

Usage

All these reagents are effectively formulated for direct immunofluorescent staining of human tissue for flow cytometric analysis using 10 µL/10^6 leukocytes for singles and 20 µL/10^6 leukocytes in case of dual and triple combinations. Since applications vary, each investigator should titrate the reagent to obtain optimal results.

Representative Data

Staining with clone B-ly7 (CD103) / B-ly8 (CD22) monoclonal antibodies is illustrated by flow cytometry analysis of HCl spleen cells. Direct staining was performed using 20 µl of the dual and 100 µl cell suspension.



Reproducibility

Monoclonal antibodies from IQ Products were tested by flow cytometry using IQ Lyse (IQP-199). The used 'lyse-wash' method is on whole blood from healthy donors. Obtained data support the premise that these reagents are equivalent in their reactivity with peripheral blood lymphocytes. Values are expressed in terms of % of the total lymphocyte count (see table).

Reagent	N	Mean % positive	S.D.	%CV
CD103 FITC	10	92,08	1,31	1,42
CD22 R-PE	10	13,36	3,89	29,12

Limitations

1. Conjugates with brighter fluorochromes, like PE and APC, will have a greater separation than those with dyes like FITC and CyQ. When populations overlap, the percentage of positive cells using a selected marker can be affected by the choice of fluorescent label.
2. Use of monoclonal antibodies in patient treatment can interfere with antigen target recognition by this reagent. This should be taken into account when samples are analyzed from patients treated in this fashion. IQ Products has not characterized the effect of the presence of therapeutic antibodies on the performance of this reagent.
3. Reagents can be used in different combinations, therefore laboratories need to become familiar performance characteristics of each antibody in relation with the combined markers in normal and abnormal samples.
4. Reagent data performance is based on EDTA-treated blood. Reagent performance can be affected by the use of other anticoagulants.

Reagents and materials required but not supplied

1. Flow cytometer
2. Flow cytometry disposable 12 x 75-mm capped polystyrene test tubes
3. Micropipette with disposable tips
4. Vortex mixer
5. Centrifuge
6. IQ Lyse - erythrocyte lysing solution (IQP-199)
7. IQ Starfiqs - fixation and permeabilization solution (IQP-200)
8. PBS (phosphate-buffered saline)
9. 1% Heparin
10. 1% paraformaldehyde solution in PBS (store at 2-8 °C in amber glass for up to 1 week)

Immunofluorescence staining and lysing protocol

Flow cytometry method for use with dual and triple combinations

1. Add 100 µl of EDTA-treated blood (i.e. approx. 10^6 leukocytes) to a 5 ml reagent tube. The content of one tube is sufficient to perform one test.
   For combinations with anti-kappa and/or anti-lambda Ig see application note below.
2. Add to each tube 20 µl of labeled monoclonal antibody combination*.
3. Vortex the tube to ensure thorough mixing of antibody and cells.
4. Incubate the tube for 15 minutes at room temperature in the dark.
5. Add 100 µl of IQ Lyse (IQP-199 ready-to-use) and mix immediately.
6. Incubate for 10 minutes at room temperature in the dark.
7. Add 2 ml of demineralized water and incubate for 10 minutes in the dark.
8. Centrifuge the labeled cell suspension for 2 minutes at 1000 x g.
9. Remove the supernatant and resuspend the cells in 200 µl of PBS**.
10. Analyze by flow cytometry within four hours (alternatively, the cells may be fixed by 0.05% of formaline in buffered saline for analysis the next day. Some antigens are readily destroyed upon fixation and this should be taken into account when using this alternative).

** Appropriate mouse Ig isotype control samples should always be included in any labeling study*
*** PBS: Phosphate Buffered Saline, pH 7.2*

Application note for anti-kappa and/or anti-lambda Ig combinations

Add 2 ml of PBS containing 0.001% (v/v) Heparin (**prewarmed to 37 °C**) to the cell suspension
Vortex, centrifuge (2 min at 300x g) and discard the supernatant
Repeat this step twice
Resuspend the pelleted blood cells in 100 µl PBS containing 0.001% (v/v) Heparin

Handling and Storage

Antibodies are supplied either as 100 tests per vial (1 ml) for singles or 50 tests per vial (1 ml) for dual and triple combinations. They are supplied in 0.01 M sodium phosphate, 0.15 M NaCl; pH 7.3, 0.2% BSA, 0.09% sodiumazide (NaN_3). Store the vials at 2-8 °C. Monoclonal antibodies should be protected from prolonged exposure to light. Reagents are stable for the period shown on the vial label when stored properly.

Warranty Products sold hereunder are warranted only to conform to the quantity and contents stated on the label at the time of delivery to the customer. There are no warranties, expressed or implied, which extend beyond the description on the label of the product. IQ Products is not liable for property damage, personal injury, or economic loss caused by the product.

Characterization

To ensure consistently high-quality reagents, each batch of monoclonal antibody is tested for conformance with characteristics of a standard reagent. Representative flow cytometric data is included in this data sheet.

Warning All products contain sodiumazide. This chemical is poisonous and hazardous. Handling should be done by trained staff only.

References

1. Poppema, S. and Visser, L., 1990. Blood, 75: 320-321
2. Visser, L. and Poppema, S., 1990. Br. J. Haematol., 75: 359-365
3. Mulligan, S.P. et al., 1990. Blood, 76: 959-964
4. Visser, L. et al. 1992. Hematol. Pathol., 6: 37-42
5. Micklem, K.J. et al.. 1991. American Journal of Pathology, 139: 1297-130
6. Poppema, S. and Visser, L., 1987, Biotest Bulletin, 3: 131-139
7. Visser, L.. et al.. 1989. Blood, 74: 320-325
8. Poppema, S. et al., 1989, 132-134, Leucocyte Typing IV, Knapp, W., ed., Oxford University Press
9. Juliusson, G. et al.. 1994. Blood, 83: 3672-3681
10. Robbins, B.A. et al.., 1993. Blood, 82: 1277-1287
11. Pinto, A. et al. 1994. A comprehensive review based on the 5th International Workshop on Leucocyte differentiation antigens. Boston, USA, 3-7 November, 1993., 8: 347-358
12. Pich A, Fraire F, Fornari A, Bonino LD, Godio L, Bortolin P, Chiusa L, Palestro G. Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study. Eur J Haematol. 2006 May;76(5):392-8.
13. Hendrickx A, Bossuyt X. Quantification of the leukocyte common antigen (CD45) in mature B-cell malignancies. Cytometry. 2001 Dec 15;46(6):336-9.

Explanation of used symbols

	Consult instructions for use
REF	Catalogue number
	Sufficient for
IVD	In Vitro Diagnostic medical device
	Caution, consult accompanying document
	Keep away from (sun)light
	Biological risks
	Temperature limitation (°C)
RUO	For Research Use Only
LOT	Batch code
	Use by yyyy-mm-dd
	Manufacturer
EC REP	Authorized Representative in the European Community
CE	Conformité Européenne (European Conformity)

		Label - tandem	**Ex -max (nm)**	**Em -max (nm)**
P	PURE	purified material	-	-
F	FITC	FITC	488	519
R	R-PE	PE	488, 532	578
C	CyQ	PE-Cy5.18	488, 532	667
A	APC		595, 633, 635, 647	660
PC	PerCP		488, 532	678
PCC	PerCP-Cy5.5		488, 532	695

IQ Products BV
Rozenburglaan 13a
9727 DL Groningen, The Netherlands

☎ +31 (0)50 57 57 000
🖷 +31 (0)50 57 57 002
Technical marketing@iqproducts.nl
Orders orders@iqproducts.nl
www.iqproducts.nl